| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Enterovirus capsid proteins VP4 and VP2, and N‑myristoyltransferase (NMT). 2‑Hydroxytetradecanoic acid inhibits the cleavage between VP4 and VP2, blocking viral maturation. It also inhibits protein myristoylation via 2‑hydroxymyristoyl‑CoA.
|
|---|---|
| ln Vitro |
In cell‑free assays, 2‑Hydroxytetradecanoic acid inhibits the cleavage between enterovirus capsid proteins VP4 and VP2, thereby exerting antiviral activity. It also acts as an analog of myristic acid that becomes metabolically activated to 2‑hydroxymyristoyl‑CoA, which is a potent inhibitor of protein myristoylation by N‑myristoyltransferase.
|
| ln Vivo |
In vivo, 2‑Hydroxytetradecanoic acid has antiviral activity against enteroviruses, including poliovirus and coxsackievirus. It inhibits viral replication by blocking the proteolytic cleavage of VP0 into VP4 and VP2, thereby preventing the formation of mature viral capsids and infectious viral particles.
|
| Enzyme Assay |
A general cell‑free protocol for assessing N‑myristoyltransferase inhibition: Recombinant N‑myristoyltransferase (NMT) is incubated with a peptide substrate (e.g., a 20‑mer peptide containing an N‑terminal glycine) and varying concentrations of 2‑Hydroxytetradecanoic acid (0.1‑100 uM) in assay buffer (50 mM Tris‑HCl, pH 7.5, 5 mM MgCl2, 1 mM EDTA, 1 mM DTT, 0.5 mM EGTA, 0.1% Triton X‑100) containing 10 uM myristoyl‑CoA and 5 uM [3H]‑myristoyl‑CoA. After 20 minutes at 30degC, the reaction is stopped, and the incorporated radioactivity is measured to calculate the IC50.
|
| Cell Assay |
A general cellular protocol for 2‑Hydroxytetradecanoic acid: Enterovirus‑infected cells (e.g., HeLa cells infected with poliovirus or coxsackievirus) are seeded in 6‑well plates. Cells are treated with 2‑Hydroxytetradecanoic acid at concentrations of 1, 10, 50, 100 uM for 8‑24 hours post‑infection. Viral capsid protein processing (VP0 cleavage into VP4 and VP2) is assessed by Western blot. Viral titers in the culture supernatant are determined by plaque assay. Cell viability is measured by MTT assay.
|
| Animal Protocol |
A general animal protocol for 2‑Hydroxytetradecanoic acid: For an enterovirus infection model, male BALB/c mice are infected with coxsackievirus B3 (CVB3) or poliovirus via intraperitoneal injection. 2‑Hydroxytetradecanoic acid is formulated in a suitable vehicle (e.g., 10% DMSO, 40% PEG300, 5% Tween‑80, 45% saline) and administered via IP injection at doses of 10, 30, and 100 mg/kg daily for 5‑7 days post‑infection. Survival is monitored daily. At the end of the study, heart, pancreas, and other target tissues are harvested for viral load quantification by qRT‑PCR and histopathology (H&E staining).
|
| ADME/Pharmacokinetics |
General PK protocol for 2‑Hydroxytetradecanoic acid: Male Sprague‑Dawley rats are administered the compound via IV (2 mg/kg) and IP (10 mg/kg). Blood samples are collected at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 hours. Plasma concentrations are quantified by LC‑MS/MS. PK parameters (Cmax, Tmax, AUC, t1/2, clearance, Vd, and IP bioavailability) are calculated. The compound has a molecular weight of 244.37.
|
| Toxicity/Toxicokinetics |
General toxicity protocol for 2‑Hydroxytetradecanoic acid: A 14‑day repeat‑dose IP toxicity study is performed in ICR mice. 2‑Hydroxytetradecanoic acid is administered at doses of 10, 30, and 100 mg/kg/day. Parameters include clinical signs, body weight, food consumption, hematology (CBC), serum chemistry (ALT, AST, BUN, creatinine), and histopathology of major organs (liver, kidney, spleen, heart, pancreas).
|
| References | |
| Additional Infomation |
2-Hydroxymyristic acid is a long-chain fatty acid, a derivative of myristic acid, with a hydroxyl substituent at the C-2 position. It is a 2-hydroxy fatty acid and a long-chain fatty acid, and also the conjugate acid of 2-hydroxymyristic acid ester. 2-Hydroxytetradecanoic acid has been reported to be found in Brassica napus, Suberites massa, and Pseudosuberites; relevant data have been reported.
2‑Hydroxytetradecanoic acid has a molecular formula of C14H28O3 and a molecular weight of 244.37 g/mol. It is also known as 2‑Hydroxymyristic acid. The compound is a hydroxy fatty acid that inhibits protein myristoylation and enterovirus capsid processing. It is soluble in DMSO and ethanol. As a myristic acid analog, it has been used to study the role of protein myristoylation in viral replication and signal transduction. The powder can be stored at -20degC for up to 3 years. |
| Molecular Formula |
C14H28O3
|
|---|---|
| Molecular Weight |
244.37
|
| Exact Mass |
244.203
|
| CAS # |
2507-55-3
|
| PubChem CID |
1563
|
| Appearance |
Solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
377.5±15.0 °C at 760 mmHg
|
| Melting Point |
51.00 °C. @ 760.00 mm Hg
|
| Flash Point |
196.3±16.9 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.467
|
| LogP |
5.15
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
17
|
| Complexity |
180
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCC(C(=O)O)O
|
| InChi Key |
JYZJYKOZGGEXSX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H28O3/c1-2-3-4-5-6-7-8-9-10-11-12-13(15)14(16)17/h13,15H,2-12H2,1H3,(H,16,17)
|
| Chemical Name |
2-hydroxytetradecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0922 mL | 20.4608 mL | 40.9216 mL | |
| 5 mM | 0.8184 mL | 4.0922 mL | 8.1843 mL | |
| 10 mM | 0.4092 mL | 2.0461 mL | 4.0922 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
